There are currently 414 clinical trials in Las Vegas, Nevada looking for participants to engage in research studies. Trials are conducted at various facilities, including Comprehensive Cancer Centers of Nevada, University Medical Center of Southern Nevada, Summerlin Hospital Medical Center and Alliance for Childhood Diseases/Cure 4 the Kids Foundation. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/05/2024
Locations: Site 344, Las Vegas, Nevada
Conditions: Major Depressive Disorder
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Las Vegas Urology - Pecos, Las Vegas, Nevada +36 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)
NCT06483945
Recruiting
"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/28/2024
Locations: Palm Research Center, Las Vegas, Nevada
Conditions: Diabetes
Register for Updates
A Post-Market Domestic (US) and International Data Collection to Assess the Truliant Knee System
NCT05653102
Recruiting
A Post-Market Domestic (US) and International Data Collection to Assess the Truliant® Knee System
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Nevada Orthopaedic and Spine Center, Las Vegas, Nevada
Conditions: Knee Arthroplasty, Total
Register for Updates
IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery
NCT05954767
Recruiting
This study evaluates the safety and efficacy of intravenous injection of IS-001 to aid in intraoperative ureter structure delineation.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2024
Locations: MountainView Hospital, Las Vegas, Nevada
Conditions: Ureter Injury
Register for Updates
Hydrus® Microstent New Enrollment Post-Approval Study
NCT04553523
Recruiting
The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
05/28/2024
Locations: Center for Sight, Las Vegas, Nevada
Conditions: Primary Open Angle Glaucoma
Register for Updates
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
NCT04092673
Recruiting
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Conditions: Solid Tumor, Adult
Register for Updates
Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
NCT06429280
Recruiting
Amblyopia is the most prevalent cause of reduced monocular visual acuity in children and young adults, with estimates of prevalence ranging from 1% to 5%. The most common associated amblyogenic risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced visual acuity, amblyopic patients may also have measurable dysfunction of accommodation, fixation, binocularity, vergence, reading fluency, depth perception, and contrast sensitivity. For the first t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/20/2024
Locations: Nevada Eye Physicians, Las Vegas, Nevada
Conditions: Amblyopia
Register for Updates
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05997017
Recruiting
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Women's Cancer Center of Nevada, Las Vegas, Nevada
Conditions: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
Register for Updates
Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
NCT06403605
Recruiting
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available SOC treatments for Diabetic Foot Wounds.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: Wound Care Experts, Las Vegas, Nevada
Conditions: Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
Register for Updates
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364
Recruiting
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Las Vegas Urology - Pecos, Las Vegas, Nevada +28 locations
Conditions: Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Low Grade Fallopian Tube Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Ovarian Low Grade Serous Adenocarcinoma
Register for Updates
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05797831
Recruiting
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Women's Cancer Center of Nevada, Las Vegas, Nevada
Conditions: Endometrial Cancer
Register for Updates